Brief: Aptorum Group Ltd Completion Of End Of Phase 1 Meeting With US FDA On Its Sact-1 Drug Targeting Neuroblastoma

Aptorum

03/03/2023 12:39

March 3 (Reuters) - Aptorum Group Ltd  APM.O :
    * COMPLETION OF END OF PHASE 1 (EOP1) MEETING WITH US FDA ON
ITS
SACT-1, A REPURPOSED SMALL MOLECULE DRUG TARGETING NEUROBLASTOMA
    * FDA GENERALLY AGREED WITH CHEMISTRY-MANUFACTURING-CONTROL
(CMC)
STRATEGY AND OUR PROPOSED CLINICAL DEVELOPMENT PLAN FOR PHASE
1/2 TRIALS

Source text for Eikon:  ID:nBwvH7nja 
Further company coverage:  APM.O